[Peptide geroprotector application for treatment of elderly and senile patients with prostatic hyperplasia].
Gomberg VG, Ryzhak VG, Liutov RV · 2013 · Advances in gerontology = Uspekhi gerontologii · PMID 24640697
What does this source report?
A blinded placebo-controlled report describes improved urination measures and quality of life persisting one month after treatment.
- Population and setting
- Men aged 62–83 with benign prostatic hyperplasia; sample size absent from abstract
- Evidence type
- Randomized trial
- Preparation
- See the original report; formulation details require verification.
- Source language
- English indexed abstract; original language:
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Full group sizes, effect estimates and adverse-event ascertainment are unavailable in the abstract; prostate disease reversal is not established.
- Full methods, reporting completeness and independent replication remain to be appraised.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Abstract reviewed
Source access and review scope
Primary citation and indexed abstract reviewed through Europe PMC. Full article not appraised.
Recorded source-check date: 2026-10-05. This date does not imply a completed systematic review.
Source provenance: Original journal report
Cite and trace this record
Original source: Gomberg VG, Ryzhak VG, Liutov RV. [Peptide geroprotector application for treatment of elderly and senile patients with prostatic hyperplasia]. Advances in gerontology = Uspekhi gerontologii · PMID 24640697 2013.
Molekul research summary: https://molekul.io/research/audit-24640697. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry